Guinea pigs, each with an established, syngeneic dermal tumor (line-10) and microscopic lymph node metastasis, were treated by intradermal inoculation of living line-10 tumor cells admixed with emulsified heat-killed Mycobacterium bovis BCG cells. This treatment caused complete regression of established dermal tumors (about 10 mm in diameter) and prevented the growth of microscopic lymph node metastases in 25 of 39 treated animals (64%). All control animals treated by intradermal inoculation with heat-killed M. bovis BCG cells attached to oil droplets died with progressive dermal and lymphatic tumor growth.
The guinea pig line-10 (L10) tumor model has been used in studies of immunotherapy. Vaccines containing L10 cells and mycobacterial preparations were used to treat guinea pigs challenged intradermally with L10 cells immediately before vaccination (3-6), or 2 days after the excision of 7-day-old dermal tumors (1, 16) . In this report we tested the capability of vaccination to cause regression of established dermal tumors and lymph node metastases without surgical intervention.
All experiments were done with an ascitic variant of tumor L10 derived from a hepatocarcinoma induced by diethylnitrosamine in a strain 2 male guinea pig. Intradermal inoculation of 106 L1O cells resulted in progressive intradermal tumor growth, and by 1 week, tumor cells were present in the draining axillary lymph nodes; guinea pigs usually died 2 to 3 months later (10 bovis BCG cell walls in emulsified oil were inoculated intradermally into guinea pigs 2 days after the excision of 7-day-old dermal L10 (1). (iii) The growth of tumor at the vaccinated sites in tumor-bearing animals was significantly reduced when a mixture of 9 x 106 tumor cells and 3 mg of KCE was divided equally among three sites such that three regional lymph node chains were affected by the vaccine (group 3); in six of eight animals the tumor cells did not grow at the vaccinated sites (P < 0.05; in comparison with group 1 or 2), and in four of these animals, the established tumors were eradicated (P < 0.05, in comparison with group 1 or 2). aGuinea pigs, each with a 7-day-old intradermal tumor on their left side (about 2.5 cm posterior to and on line with the superficial distal axillary lymph node), were vaccinated intradermally with mixtures of living L10 cells plus KCE. Animals which were vaccinated on one site received six, 0.1-ml injections of vaccine, on the right side about 2 cm posterior to and on line with the superficial distal axillary lymph node. Animals which were vaccinated on three sites received two, 0.1-ml injections of vaccine per site. The three vaccination sites were on the right and left flanks about 2 cm anterior to and on line with the superficial inguinal lymph nodes and on the right side about 2.5 cm posterior to and on line with the superficial distal axillary lymph node.
bTumor-free animals means complete disappearance of the dermal tumor and no clinical evidence of metastastic disease at least 90 days after vaccination. No growth of tumor occurred at vaccination sites in these animals.
P p values were obtained from 2 x 2 -contingency tables of the Fisher exact test; test groups were compared with control groups (no treatment or KCE alone). M. bovis BCG cell walls in emulsified oils, prepared by a grinding method, were used as an adjuvant in previous active specific immunotherapy studies (1, 5, 6, 16 In the studies reported here, we were able to cure 25 of 39 animals, each with a relatively large dermal tumor (about 10 mm in diameter) and microscopic lymph node metastases. For about 2 weeks after vaccination, it was not possible to distinguish between the growth of the tumor in the control group and that in the group treated with the specific vaccine. However, 7 days later (21 days after vaccination), regression of the dermal tumor was apparent. Previous studies (15) have shown that 14-day-old intradermal tumors are sixfold heavier than 7-dayold tumors. In the studies reported here, the dermal tumor regressed in some animals, whereas the lymph node metastases continued to grow in others. This phenomenon might reflect a greater efficacy of tumor suppressive activity in the skin than in the lymph nodes. Similar observations have been reported previously (8, 11 In conclusion, vaccination against cancer in guinea pigs has a potential to eradicate not only microscopic lymph node metastases, but also a relatively large tumor burden in the skin. The number of sites at which the vaccine is given and the quantitative composition of the vaccine have a substantial effect on the efficacy of active specific immunotherapy.
